Synthetic Biologics Inc (SYN) : During the past 4 weeks, traders have been relatively bearish on Synthetic Biologics Inc (SYN), hence the stock is down -7.81% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.96% relative to the S&P 500. The 4-week change in the price of the stock is -8% and the stock has fallen -3.59% in the past 1 week.
For this week, the average consensus of the company shares are rated as a Strong Buy. The stock has recorded a twenty day Moving Average of 4% and the fifty day Moving Average is 7.18%. Synthetic Biologics Inc. has dropped 24.06% during the last three month period . Year-to-Date the stock performance stands at -29.69%.
Synthetic Biologics Inc (SYN) : The highest short term price target forecast on Synthetic Biologics Inc (SYN) is $9 and the lowest target price is $7. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $8.25 with a standard deviation of $0.96.
Synthetic Biologics Inc (NYSEMKT:SYN): The stock was completely flat for the day, closing at $1.61 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.59, the stock touched an intraday high of $1.64 and a low of $1.56. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.61. The total trading volume on Friday was 226,818.
Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.